Literature DB >> 11554614

Pooled umbilical cord blood as a possible universal donor for marrow reconstitution and use in nuclear accidents.

N Ende1, S Lu, M G Alcid, R Chen, R Mack.   

Abstract

Human umbilical cord blood has been shown to be an effective source of stem cells for marrow reconstitution in pediatric patients. Unfortunately, the quantity of stem cells obtained from an individual donor can be quite limited in both the total volume and the numbers of stem cells per ml of cord blood. HLA matching further limits the availability, but recent publications indicate close matching may be unnecessary. Therefore, if cord blood from different donors can be combined, larger numbers of stem cells can be available for clinical use provided pooling does not produce a negative effect. Storage of single cord blood specimens at 4 degrees C for 10-21 days in gas permeable bags produced an apparent increase in the percentage of immature cells (CD34, CD117, GPA) and mitotic activity (S+G2/M cells) over day 1. With similar storage of pooled specimens there was a further increase in the number of immature colonies cultured, CD34, CD117, GPA, S+G2/M cells. In addition, nucleated red blood cells increased over the mean values obtained from single cord blood samples. Our previous studies have indicated that large numbers of human mononuclear cells are necessary to reconstitute an irradiated animal model. By combining multiple samples of human cord blood, adequate numbers of stem cells could be pooled for use in adults and would provide cells for megadose therapy, including those patients that had accidentally received lethal irradiation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554614     DOI: 10.1016/s0024-3205(01)01245-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Production of stem cells with embryonic characteristics from human umbilical cord blood.

Authors:  C P McGuckin; N Forraz; M-O Baradez; S Navran; J Zhao; R Urban; R Tilton; L Denner
Journal:  Cell Prolif       Date:  2005-08       Impact factor: 6.831

Review 2.  Potential for access to embryonic-like cells from human umbilical cord blood.

Authors:  C P McGuckin; N Forraz
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

Review 3.  Promising new sources for pluripotent stem cells.

Authors:  Christian Leeb; Marcin Jurga; Colin McGuckin; Richard Moriggl; Lukas Kenner
Journal:  Stem Cell Rev Rep       Date:  2010-03       Impact factor: 5.739

4.  The necessity of the early use of antibiotics in treatment of mass casualties from ionizing radiation.

Authors:  Norman Ende; Olga A Kovalenko; Edouard I Azzam
Journal:  Int J Radiat Biol       Date:  2011-12-20       Impact factor: 2.694

5.  Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop.

Authors:  Andrea L DiCarlo; Radia Tamarat; Carmen I Rios; Marc Benderitter; Christine W Czarniecki; Theresa C Allio; Francesca Macchiarini; Bert W Maidment; Jean-Rene Jourdain
Journal:  Radiat Res       Date:  2017-06-12       Impact factor: 2.841

6.  Ultrasensitive Quantitation of Genomic Chimerism by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing of Copy Number Deletion Polymorphisms.

Authors:  David Wu; Sami B Kanaan; Kelsi Penewit; Adam Waalkes; Francesca Urselli; J Lee Nelson; Jerald Radich; Stephen J Salipante
Journal:  J Mol Diagn       Date:  2021-11-11       Impact factor: 5.568

7.  Ultrasensitive Detection of Chimerism by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing of Copy Number Deletion Polymorphisms.

Authors:  David Wu; Adam Waalkes; Kelsi Penewit; Stephen J Salipante
Journal:  Clin Chem       Date:  2018-03-16       Impact factor: 8.327

8.  Human umbilical-cord-blood mononucleated cells enhance the survival of lethally irradiated mice: dosage and the window of time.

Authors:  Olga A Kovalenko; Edouard I Azzam; Norman Ende
Journal:  J Radiat Res       Date:  2013-06-21       Impact factor: 2.724

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.